Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma.

Ching Ngar WongPetros FessasKathy DominyFrancesco A MauriTakahiro KanekoPersephone Du ParcqJamshid KhorashadPierluigi ToniuttoRobert D GoldinClaudio AvelliniDavid James Pinato

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

While tNGS on fresh HCC samples appears to be the optimal source of tumour DNA, the low median TMB values observed may limit the role of TMB as a predictor of response to immunotherapy in HCC.

Keyphrases

circulating tumor
cell free
single molecule
cancer therapy
copy number
circulating tumor cells
risk factors
dna methylation
drug delivery